Q-omics provides the consensus-scored LINC01705 profile across patient tissues and cancer cell-line models. LINC01705 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01705 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, LINC01705 RNA expression shows 15,072 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, COAD, and PDAC as cancer lineages where LINC01705 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01705 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01705 survival associations across molecular data types. LINC01705 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01705 RNA expression–survival associations across cancer types. High LINC01705 expression shows unfavorable associations in KIRP, ACC, KIRC, PAAD, MESO and STAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01705 RNA expression.
This table summarizes LINC01705 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01705. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01705 shows higher tumor expression in COAD, BLCA, KIRC, LUAD, BRCA and LUSC. The COAD box plot shows higher LINC01705 RNA expression in tumor versus normal tissue (log2 FC = +2.230, t-test p < 0.001).
This table shows molecular features associated with LINC01705 in patient tissues and cancer cell lines. In patient samples, LINC01705 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
